WO2001087849A3 - Modulators of tnf- alpha signaling - Google Patents
Modulators of tnf- alpha signaling Download PDFInfo
- Publication number
- WO2001087849A3 WO2001087849A3 PCT/US2001/015027 US0115027W WO0187849A3 WO 2001087849 A3 WO2001087849 A3 WO 2001087849A3 US 0115027 W US0115027 W US 0115027W WO 0187849 A3 WO0187849 A3 WO 0187849A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tnf
- modulators
- alpha signaling
- signaling
- alpha
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
Abstract
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2408408A CA2408408C (en) | 2000-05-12 | 2001-05-10 | Modulators of tnf- alpha signaling |
JP2001584245A JP4960565B2 (en) | 2000-05-12 | 2001-05-10 | Modulator of TNFα signaling |
EP01933253.5A EP1294699B1 (en) | 2000-05-12 | 2001-05-10 | Modulators of tnf- alpha signalling |
AU5969101A AU5969101A (en) | 2000-05-12 | 2001-05-10 | Modulators of tnf-alpha signaling |
BR0111158A BR0111158A (en) | 2000-05-12 | 2001-05-10 | Compound and physiological salts thereof, method for treating a median condition by tnf-a in a patient |
IL15245001A IL152450A0 (en) | 2000-05-12 | 2001-05-10 | COMPOUNDS HAVING TNF-alpha SIGNAL MODULATING ACTIVITY |
MXPA02010993A MXPA02010993A (en) | 2000-05-12 | 2001-05-10 | MODULATORS OF TNF agr; SIGNALING. |
AU2001259691A AU2001259691B2 (en) | 2000-05-12 | 2001-05-10 | Modulators of TNF-alpha signaling |
KR1020027015152A KR100840816B1 (en) | 2000-05-12 | 2001-05-10 | MODULATORS OF TNF-¥áSIGNALING |
IL15245002A IL152450A (en) | 2000-05-12 | 2002-10-24 | Compounds and compositions for use in treating tnf-?? mediated conditions |
NO20025405A NO324693B1 (en) | 2000-05-12 | 2002-11-11 | 2-acetamidoacetamide derivatives, use of such compounds for the preparation of compositions for the treatment of diseases and preparations comprising such compounds |
HK03103293.5A HK1051186A1 (en) | 2000-05-12 | 2003-05-12 | Modulators of tnf-alpha signalling tnf- |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20378400P | 2000-05-12 | 2000-05-12 | |
US60/203,784 | 2000-05-12 | ||
US20521300P | 2000-05-18 | 2000-05-18 | |
US60/205,213 | 2000-05-18 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001087849A2 WO2001087849A2 (en) | 2001-11-22 |
WO2001087849A3 true WO2001087849A3 (en) | 2002-06-06 |
Family
ID=26898898
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/015027 WO2001087849A2 (en) | 2000-05-12 | 2001-05-10 | Modulators of tnf- alpha signaling |
Country Status (13)
Country | Link |
---|---|
US (5) | US6969728B2 (en) |
EP (1) | EP1294699B1 (en) |
JP (3) | JP4960565B2 (en) |
KR (1) | KR100840816B1 (en) |
CN (1) | CN100494182C (en) |
AU (2) | AU5969101A (en) |
BR (1) | BR0111158A (en) |
CA (3) | CA2408408C (en) |
HK (1) | HK1051186A1 (en) |
IL (2) | IL152450A0 (en) |
MX (1) | MXPA02010993A (en) |
NO (1) | NO324693B1 (en) |
WO (1) | WO2001087849A2 (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2408408C (en) * | 2000-05-12 | 2013-07-09 | Genzyme Corporation | Modulators of tnf- alpha signaling |
DE10108481A1 (en) * | 2001-02-22 | 2002-10-24 | Bayer Ag | pyridylpyrimidines |
CZ305099B6 (en) * | 2001-04-10 | 2015-05-06 | Pfizer Inc. | Pyrazole derivative, process and intermediates to the preparation thereof, pharmaceutical composition containing the derivative and medicinal application thereof particularly for treating HIV infection |
NZ534757A (en) * | 2002-03-12 | 2006-07-28 | Merck & Co Inc | Substituted amides |
PT1567138E (en) * | 2002-11-21 | 2011-04-11 | Genzyme Corp | Use of a diamide derivative for inhibiting chronic transplant rejection |
JP4914008B2 (en) * | 2002-11-21 | 2012-04-11 | ジェンザイム・コーポレーション | Combinations of diamide derivatives and immunosuppressive agents for inducing immune tolerance |
JP4897221B2 (en) * | 2002-12-20 | 2012-03-14 | チバ ホールディング インコーポレーテッド | Synthesis of amines and intermediates for their synthesis |
WO2004071383A2 (en) * | 2003-02-11 | 2004-08-26 | Boehringer Ingelheim International Gmbh | New pharmaceutical compositions based on anticholinergics and inhibitors of tnf alpha synthesis or action |
US7977366B2 (en) * | 2003-10-14 | 2011-07-12 | Cornell Research Foundation, Inc. | Treating an inflammatory disorder or inhibiting respiratory burst in adherent neutrophils with chemical inhibitors of neutrophil activation |
EP1765347A4 (en) * | 2004-06-04 | 2008-10-01 | Univ California | Compounds having activity in increasing ion transport by mutant-cftr and uses thereof |
KR20080089461A (en) * | 2005-12-30 | 2008-10-06 | 랜박시 래보러터리스 리미티드 | Muscarinic receptor antagonists |
US20080003230A1 (en) | 2006-07-03 | 2008-01-03 | Adair Charles D | Composition for modulating the expression of cell adhesion molecules |
EP2079728B1 (en) | 2006-10-10 | 2013-09-25 | Amgen Inc. | N-aryl pyrazole compounds for use against diabetes |
WO2009026579A1 (en) * | 2007-08-23 | 2009-02-26 | Cornell Research Foundation, Inc. | Proteasome inhibitors and their use in treating pathogen infection and cancer |
WO2009073146A2 (en) * | 2007-11-29 | 2009-06-11 | Celgene Corporation | Use of immunomodulatory compounds for the treatment of transverse myelitis, multiple sclerosis, and other disorders |
EP2827861A4 (en) * | 2012-03-19 | 2016-03-16 | Aposignal Bioscience Llc | Composition and methods for cell modulation |
UY36034A (en) | 2014-03-18 | 2015-09-30 | Astrazeneca Ab | DERIVATIVES OF 3,5-DIAMINO-6-CHLORINE-PIRAZINA-2-CARBOXAMIDE AND PHARMACEUTICALLY ACCEPTABLE SALTS OF THESE |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2937698A1 (en) * | 1979-09-18 | 1981-04-02 | A. Nattermann & Cie GmbH, 5000 Köln | N-PROPIONYLSARCOSINANILIDES, THEIR PRODUCTION METHOD AND MEDICINAL PRODUCTS BASED ON THEM |
JPH01101456A (en) * | 1987-10-15 | 1989-04-19 | Honda Electron Co Ltd | Ultrasonic microscope device |
WO1999000363A1 (en) * | 1997-06-27 | 1999-01-07 | Pharmacia & Upjohn S.P.A. | Substituted triazine compounds and their use in medicine |
US6048841A (en) * | 1995-11-22 | 2000-04-11 | Darwin Discovery, Ltd. | Peptidyl compounds |
WO2000026209A1 (en) * | 1998-11-03 | 2000-05-11 | Novartis Ag | Anti-inflammatory 4-phenyl-5-pyrimidinyl-imidazoles |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE372326C (en) | 1922-04-22 | 1923-03-26 | Adam Thierauf | Turbine system |
DE748704C (en) | 1938-02-26 | 1944-11-08 | Device for resiliently limiting the longitudinal play of the armature shaft of small electric motors running in plain bearings | |
CA996119A (en) | 1971-12-10 | 1976-08-31 | Eastman Kodak Company | Oxichromic compounds, stabilized oxichromic compounds and processes for preparing same |
US3935263A (en) * | 1971-12-10 | 1976-01-27 | Eastman Kodak Company | Oxichromic compounds, stabilized oxichromic compounds and processes for preparing same |
US5672347A (en) * | 1984-07-05 | 1997-09-30 | Genentech, Inc. | Tumor necrosis factor antagonists and their use |
EP0246749A3 (en) | 1986-05-17 | 1988-08-31 | AgrEvo UK Limited | Triazole herbicides |
DE3825867A1 (en) | 1988-03-04 | 1989-09-14 | Bayer Ag | HETEROCYCLICALLY SUBSTITUTED SULFONYLAMINOAZOLES AND THEIR USE AS HERBICIDES |
DE3813886A1 (en) | 1988-04-20 | 1989-11-02 | Schering Ag | 1-Triazinyl-1H-1,2,4-triazole-3-sulphonamides, processes for their preparation, and their use as herbicides, fungicides and plant growth regulators |
US4944796A (en) * | 1988-11-14 | 1990-07-31 | Ici Americas Inc. | Certain 2-(disubstituted amino) acetanilide herbicides |
DE3841086A1 (en) | 1988-12-07 | 1990-06-21 | Bayer Ag | SULFONYLAMINOAZINE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS HERBICIDES |
US5540931A (en) * | 1989-03-03 | 1996-07-30 | Charles W. Hewitt | Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants |
US4997950A (en) * | 1989-04-20 | 1991-03-05 | Richard Finbar Murphy | Novel C-terminal gastrin antagonists |
US5100899A (en) | 1989-06-06 | 1992-03-31 | Roy Calne | Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof |
DE3928605A1 (en) | 1989-08-30 | 1991-03-07 | Bayer Ag | SUBSTITUTED SULFONYLAMINOAZOLES |
JPH0686378B2 (en) * | 1990-05-31 | 1994-11-02 | 田辺製薬株式会社 | Immunomodulator |
US5958413A (en) * | 1990-11-01 | 1999-09-28 | Celltech Limited | Use of antibodies to TNF or fragments derived thereof and xanthine derivatives for combination therapy and compositions therefor |
US6420374B1 (en) * | 1990-11-30 | 2002-07-16 | Fred Hutchinson Cancer Research Center | Use of xanthines as immunosuppressants and to inhibit allograft reactions |
WO1992017456A1 (en) * | 1991-03-26 | 1992-10-15 | Fujisawa Pharmaceutical Co., Ltd. | Amino acid derivative and salt thereof |
EP0520573A1 (en) | 1991-06-27 | 1992-12-30 | Glaxo Inc. | Cyclic imide derivatives |
WO1993017009A1 (en) | 1992-02-28 | 1993-09-02 | Zenyaku Kogyo Kabushiki Kaisha | s-TRIAZINE DERIVATIVE AND REMEDY FOR ESTROGEN-DEPENDENT DISEASES CONTAINING THE SAME AS ACTIVE INGREDIENT |
US5861382A (en) * | 1992-05-01 | 1999-01-19 | Yeda Research And Development Co. Ltd. | Methods for regulation of active TNF-α |
WO1995009652A1 (en) | 1993-10-06 | 1995-04-13 | The Kennedy Institute For Rheumatology | Treatment of autoimmune and inflammatory disorders |
US6270766B1 (en) * | 1992-10-08 | 2001-08-07 | The Kennedy Institute Of Rheumatology | Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease |
AU5152293A (en) | 1992-10-08 | 1994-05-09 | Kennedy Institute Of Rheumatology, The | Treatment of autoimmune and inflammatory disorders |
US6030615A (en) * | 1993-05-17 | 2000-02-29 | The Picower Institute For Medical Research | Combination method for treating diseases caused by cytokine-mediated toxicity |
DE4337600A1 (en) * | 1993-11-01 | 1995-05-04 | Diagnostikforschung Inst | N-alkyl peptide chelating agents, their metal complexes with radionuclides, processes for their preparation and radiopharmaceutical compositions containing these compounds |
NZ278607A (en) * | 1994-02-07 | 1999-05-28 | Knoll Ag | Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above |
DE4430127A1 (en) * | 1994-08-25 | 1996-03-14 | Hoechst Ag | Combination preparation containing cyclosporin A or FK506 and a xanthine derivative |
DE4430128A1 (en) * | 1994-08-25 | 1996-02-29 | Hoechst Ag | Combination preparation with immunosuppressive, cardiovascular and cerebral effects |
US5932737A (en) * | 1994-12-02 | 1999-08-03 | Fujisawa Pharmaceutical Co., Ltd. | Peptide compounds for treatment of no-mediated diseases |
US6306840B1 (en) | 1995-01-23 | 2001-10-23 | Biogen, Inc. | Cell adhesion inhibitors |
US5632367A (en) | 1995-01-23 | 1997-05-27 | Mars, Incorporated | Validation housing for a bill validator made by a two shot molding process |
FR2730411B1 (en) * | 1995-02-14 | 1997-03-28 | Centre Nat Rech Scient | DRUG ASSOCIATION USEFUL FOR IN VIVO TRANSFECTION AND EXPRESSION OF EXOGENES |
ATE226641T1 (en) | 1995-04-08 | 2002-11-15 | Lg Chemical Ltd | HUMAN 4-1BB SPECIFIC HUMAN ANTIBODIES AND CELL LINE PRODUCING THEM |
CA2217857A1 (en) | 1995-05-10 | 1996-11-14 | Darwin Discovery Limited | Peptide compounds which inhibit metalloproteinase and tnf liberation and their therapeutic uses |
SE510202C2 (en) | 1995-05-19 | 1999-04-26 | Stroemsholmen Ab | Device for a hydraulic system |
US5654312A (en) * | 1995-06-07 | 1997-08-05 | Andrulis Pharmaceuticals | Treatment of inflammatory and/or autoimmune dermatoses with thalidomide alone or in combination with other agents |
ATE259235T1 (en) * | 1995-07-20 | 2004-02-15 | Cell Eng Ag | PREPARATION CONTAINING GLYCANS COMPLIANT WITH TRANSFERRIN GLYCANS AS AN ACTIVE PRINCIPLE FOR THE INDUCTION OF IMMUNOTOLERANCE AGAINST ANTIGENS |
IL115245A (en) * | 1995-09-11 | 2002-12-01 | Yissum Res Dev Co | Tumor necrosis factor inhibiting pharmaceuticals |
US6090382A (en) * | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
AU2521597A (en) * | 1996-04-12 | 1997-11-07 | Sumitomo Pharmaceuticals Company, Limited | Piperidinylpyramidine derivatives |
US6211160B1 (en) * | 1996-09-06 | 2001-04-03 | The Trustees Of The University Of Pennsylvania | Method for tolerizing a mammalian patient to administration of gene therapy virus vectors |
TW520362B (en) * | 1996-12-05 | 2003-02-11 | Amgen Inc | Substituted pyrimidine compounds and pharmaceutical composition comprising same |
DE69724451T2 (en) * | 1996-12-06 | 2004-03-18 | Amgen Inc., Thousand Oaks | COMBINATION THERAPY WITH A TNF-BINDING PROTEIN FOR TREATING DISEASES CAUSED BY TNF |
DE69837322T2 (en) | 1997-01-10 | 2007-11-22 | Biogen Idec Ma Inc., Cambridge | METHOD FOR THE THERAPEUTIC ADMINISTRATION OF ANTI-CD40L MEDIUM |
US6294170B1 (en) * | 1997-08-08 | 2001-09-25 | Amgen Inc. | Composition and method for treating inflammatory diseases |
WO1998039026A2 (en) | 1997-03-07 | 1998-09-11 | Biogen, Inc. | Methods of therapeutic administration of anti-cd40l compounds |
US5801193A (en) * | 1997-04-15 | 1998-09-01 | Immune Modulation, Inc. | Compositions and methods for immunosuppressing |
US6506569B1 (en) * | 1997-05-30 | 2003-01-14 | Human Genome Sciences, Inc. | Antibodies to human tumor necrosis factor receptor TR10 |
AU8672198A (en) | 1997-07-31 | 1999-02-22 | Chiron Corporation | Method enabling readministration of aav vector via immunosuppression of host |
US6503184B1 (en) * | 1997-10-21 | 2003-01-07 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2 |
US6022884A (en) * | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
US6407218B1 (en) * | 1997-11-10 | 2002-06-18 | Cytimmune Sciences, Inc. | Method and compositions for enhancing immune response and for the production of in vitro mabs |
EP1036066B1 (en) | 1997-12-03 | 2007-04-18 | Mid-America Commercialization Corporation | Substituted pyrimidine and pyridine herbicides |
AU3368899A (en) * | 1998-03-30 | 1999-10-18 | Cambridge Neuroscience, Inc. | Protein-carbohydrate binding antagonists |
NZ507558A (en) * | 1998-05-05 | 2003-08-29 | F | Pyrazole derivatives as P-38 map kinase inhibitors |
FR2780891A1 (en) | 1998-07-10 | 2000-01-14 | Univ Paris Curie | EXCHANGE OF T LYMPHOCYTES |
US6359061B1 (en) | 1999-03-19 | 2002-03-19 | Isis Pharmaceuticals, Inc. | Amide compound libraries |
EP1165500A1 (en) * | 1999-04-02 | 2002-01-02 | Du Pont Pharmaceuticals Company | Amide derivatives as inhibitors of matrix metalloproteinases,tnf-alpha,and aggrecanase |
US6365617B1 (en) | 1999-06-29 | 2002-04-02 | Ortho-Mcneil Pharmaceutical, Inc. | Indole and indazole urea-peptoids as thrombin receptor antagonists |
US6204245B1 (en) * | 1999-09-17 | 2001-03-20 | The Regents Of The University Of California | Treatment of narcolepsy with immunosuppressants |
WO2001034649A2 (en) | 1999-11-09 | 2001-05-17 | Chiron Corporation | Compositions and methods for treating autoimmune diseases and transplant rejections |
JP2003516380A (en) | 1999-12-07 | 2003-05-13 | ノバルティス アクチエンゲゼルシャフト | VLA-4 integrin antagonist |
DE10019755A1 (en) | 2000-04-20 | 2001-11-08 | Bayer Ag | New cyclic carboxylic acids are integrin antagonists, useful for treating inflammatory diseases, autoimmune and immune disorders, e.g. atherosclerosis, asthma and diabetes |
CA2408408C (en) | 2000-05-12 | 2013-07-09 | Genzyme Corporation | Modulators of tnf- alpha signaling |
RU2270194C2 (en) * | 2000-05-22 | 2006-02-20 | Лео Фарма А/С | BENZOPHENONES AS INHIBITORS OF IL-β AND TNF-α, PHARMACEUTICAL COMPOSITION AND TREATMENT METHOD |
AU2003280429A1 (en) * | 2002-06-26 | 2004-01-19 | The Trustees Of Columbia Uninersity In The City Of New York | Use of streptavidin to inhibit transplant rejection |
JP4914008B2 (en) | 2002-11-21 | 2012-04-11 | ジェンザイム・コーポレーション | Combinations of diamide derivatives and immunosuppressive agents for inducing immune tolerance |
PT1567138E (en) * | 2002-11-21 | 2011-04-11 | Genzyme Corp | Use of a diamide derivative for inhibiting chronic transplant rejection |
-
2001
- 2001-05-10 CA CA2408408A patent/CA2408408C/en not_active Expired - Lifetime
- 2001-05-10 KR KR1020027015152A patent/KR100840816B1/en active IP Right Grant
- 2001-05-10 MX MXPA02010993A patent/MXPA02010993A/en active IP Right Grant
- 2001-05-10 BR BR0111158A patent/BR0111158A/en not_active Application Discontinuation
- 2001-05-10 AU AU5969101A patent/AU5969101A/en active Pending
- 2001-05-10 IL IL15245001A patent/IL152450A0/en unknown
- 2001-05-10 EP EP01933253.5A patent/EP1294699B1/en not_active Expired - Lifetime
- 2001-05-10 US US09/852,965 patent/US6969728B2/en not_active Expired - Lifetime
- 2001-05-10 CA CA2876779A patent/CA2876779A1/en not_active Abandoned
- 2001-05-10 WO PCT/US2001/015027 patent/WO2001087849A2/en active Application Filing
- 2001-05-10 CN CNB018127363A patent/CN100494182C/en not_active Expired - Fee Related
- 2001-05-10 CA CA 2781858 patent/CA2781858C/en not_active Expired - Lifetime
- 2001-05-10 JP JP2001584245A patent/JP4960565B2/en not_active Expired - Lifetime
- 2001-05-10 AU AU2001259691A patent/AU2001259691B2/en not_active Ceased
-
2002
- 2002-10-24 IL IL15245002A patent/IL152450A/en active IP Right Grant
- 2002-11-11 NO NO20025405A patent/NO324693B1/en not_active IP Right Cessation
-
2003
- 2003-05-12 HK HK03103293.5A patent/HK1051186A1/en not_active IP Right Cessation
-
2004
- 2004-03-10 US US10/797,244 patent/US7034031B2/en not_active Expired - Lifetime
-
2005
- 2005-12-01 US US11/292,325 patent/US8518999B2/en not_active Expired - Lifetime
-
2011
- 2011-10-14 JP JP2011226847A patent/JP5529827B2/en not_active Expired - Fee Related
-
2013
- 2013-07-19 US US13/946,389 patent/US8921547B2/en not_active Expired - Fee Related
-
2014
- 2014-03-06 JP JP2014043411A patent/JP5754040B2/en not_active Expired - Fee Related
- 2014-11-25 US US14/553,313 patent/US9579325B2/en not_active Expired - Lifetime
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2937698A1 (en) * | 1979-09-18 | 1981-04-02 | A. Nattermann & Cie GmbH, 5000 Köln | N-PROPIONYLSARCOSINANILIDES, THEIR PRODUCTION METHOD AND MEDICINAL PRODUCTS BASED ON THEM |
JPH01101456A (en) * | 1987-10-15 | 1989-04-19 | Honda Electron Co Ltd | Ultrasonic microscope device |
US6048841A (en) * | 1995-11-22 | 2000-04-11 | Darwin Discovery, Ltd. | Peptidyl compounds |
WO1999000363A1 (en) * | 1997-06-27 | 1999-01-07 | Pharmacia & Upjohn S.P.A. | Substituted triazine compounds and their use in medicine |
WO2000026209A1 (en) * | 1998-11-03 | 2000-05-11 | Novartis Ag | Anti-inflammatory 4-phenyl-5-pyrimidinyl-imidazoles |
Non-Patent Citations (7)
Title |
---|
BIOMED. ENVIRON. MASS SPECTROM., vol. 14, no. 4, - 1987, pages 173 - 182 * |
CHEMICAL ABSTRACTS, vol. 107, no. 5, 3 August 1987, Columbus, Ohio, US; abstract no. 32462w, COUTTS, R. T. ET AL.: "Acetylation and pentafluorobenzoylation of lidocaine metabolites in aqueous solution and identidication of derivatives by combined gas chromatography/mass spectrometry." XP002188016 * |
CHEMICAL ABSTRACTS, vol. 130, no. 11, 15 March 1999, Columbus, Ohio, US; abstract no. 139333g, KONDO, KAZUMI ET AL.: "Preparation of amides as vasopressin antagonists, oxytocin antagonists, and vasopressin agonists." XP002188017 * |
DATABASE CHEMICAL ABSTRACTS XP002188018 * |
DATABASE CHEMICAL ABSTRACTS XP002188019 * |
JAY WROBEL ET AL.: "Syntheses of Tolrestat analogues containing additional substituents in the ring and their evaluation as aldose reductase inhibitors. Identification of potent, orally active 2-fluoro derivatives", JOURNAL OF MEDICINAL CHEMISTRY., vol. 34, no. 8, - 1991, AMERICAN CHEMICAL SOCIETY. WASHINGTON., US, pages 2504 - 2520, XP000567039, ISSN: 0022-2623 * |
JORDI GARCIA ET AL.: "New synthetic "tricks". Triphenylphosphine-mediated amide formation from carboxylic acids and azides", TETRAHEDRON LETTERS., vol. 25, no. 42, - 1984, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM., NL, pages 4841 - 4844, XP002188015, ISSN: 0040-4039 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001087849A3 (en) | Modulators of tnf- alpha signaling | |
WO2002038107A3 (en) | Stat modulators | |
WO2003005999A8 (en) | Methods of treating cytokine mediated diseases | |
EP1496878A4 (en) | Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds | |
WO2005011592A3 (en) | Substituted indazole-o-glucosides | |
ATE305788T1 (en) | (S,S)-REBOXETINE FOR THE TREATMENT OF INCONTINENCE | |
WO2005012243A3 (en) | Substituted indole-o-glucosides | |
WO2001076514A3 (en) | Methods and devices for treating fractured and/or diseased bone | |
MXPA03007983A (en) | Process for the preparation of middle distillates. | |
WO2002012190A3 (en) | Non-imidazole aryloxypiperidines as h3 receptor ligands | |
WO2001098236A3 (en) | 7-phenyl-substituted tetracycline compounds | |
WO2003059378A3 (en) | Combined use of a glp-1 compound and another drug for treating dyslipidemia | |
WO2005115398A3 (en) | Hiv integrase inhibitors | |
WO2005021497A3 (en) | Tethered dimers and trimers of 1,4-diphenylazetidn-2-ones | |
WO2001017543A3 (en) | Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer | |
MXPA03002861A (en) | Retinoids for the treatment of emphysema. | |
AU2002336405A1 (en) | Methods for treating deodorizer distillate | |
WO2002024695A3 (en) | Octahydro-indolizines and quinolizines and hexahydro-pyrrolizines | |
WO2002020013A3 (en) | A method for treating allergies using substituted pyrazoles | |
WO2003037863A3 (en) | Substituted indoles, method for production and use thereof for the inhibition of pain | |
MXPA03001455A (en) | Pyrazole compounds, pharmaceutical compositions, and methods for modulating or inhibiting erab or hadh2 activity. | |
AU2003215190A1 (en) | Methods and compositions for treating aids and hiv-related disorders using 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784, or 2045 molecules. | |
AU2001244834A1 (en) | Novel strain for decomposing tmah, and method of wastewater treatment using the same | |
MXPA04004090A (en) | Substituted 1h-quinolin-2-one compounds. | |
HU0000531D0 (en) | Method for the correction of deuteranopia, filter used by the method and procedure for the production of the filter |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 152450 Country of ref document: IL Ref document number: 2001259691 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2408408 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2002/010993 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020027015152 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001933253 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 018127363 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 1020027015152 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2001933253 Country of ref document: EP |